Indiana University Indiana Univ. - Purdue Univ.

Indianapolis, Indiana 46202

0 studies enrolling now · 4 studies all time

What they study most

Hematologic Malignancies, Solid Tumor, Solid Tumor and Hematologic Malignancies, Tumor Pathway Activations Inhibited by Dovitinib, Tumors With CDK4/6 Pathway Activation

Studies at this site

• MEK162 for Patients With RAS/RAF/MEK Activated Tumors — Completed
• LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE) — Completed
• BGJ398 for Patients With Tumors With FGFR Genetic Alterations — Stopped early
• Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib — Completed